Anvisa Prohibits Advertising of Semaglutida Pen
- Published:
- First detected:
Insights by Echo AI
Anvisa, Brazil's health surveillance agency, has prohibited the advertising of Semavy, a semaglutida pen used to treat type 2 diabetes, due to irregular promotions on billboards at Congonhas Airport, the product's website, and social media. The medication, which requires a prescription, cannot be advertised to the general public according to Brazilian law. Hypera Pharma, the manufacturer, has been cooperative with Anvisa's directives.
Source coverage
Aggregated
3
records merged
X / Twitter
1
1 unique
Telegram
0
0 unique
RSS
2
2 unique
3 Sources
Unlock Echo Intelligence
Move beyond the public feed. Monitor breaking stories across Telegram, X, and the web — with earlier visibility, clearer context, and complete control over your sources.
- Monitor Telegram, X, and web in one place
- Add any source, from niche channels to global outlets
- Build custom feeds around events, regions, entities, or keywords
- Merge duplicate coverage into one clear, source-transparent story
- Auto-translate summaries and full articles
- Search past coverage and use AI-powered editorial tools
